678 related articles for article (PubMed ID: 30193375)
1. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
2. Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.
Al-Hilli Z; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2018 Feb; 25(2):482-493. PubMed ID: 29181679
[TBL] [Abstract][Full Text] [Related]
3. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
4. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
5. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
[TBL] [Abstract][Full Text] [Related]
6. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
7. Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy.
Weiss A; King C; Vincuilla J; Parker T; Portnow L; Nakhlis F; Dominici L; Mittendorf EA; King TA
Breast Cancer Res Treat; 2022 Sep; 195(2):181-189. PubMed ID: 35900704
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer.
Murphy BL; L Hoskin T; Heins CDN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Sep; 24(9):2518-2525. PubMed ID: 28484921
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pathological nodal burden after neoadjuvant chemotherapy in initially cN0-1 breast cancer patients: a dual-center, 10-year survival analysis.
Maimaitiaili A; Fan Z; Zhang J; Wang Y; Shi B; Zheng J; Li G; Zhao Y; Pu S; He J; Qu F; Zhang H
Ther Adv Med Oncol; 2024; 16():17588359241248318. PubMed ID: 38716480
[TBL] [Abstract][Full Text] [Related]
11. Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?
Barrio AV; Mamtani A; Eaton A; Brennan S; Stempel M; Morrow M
Ann Surg Oncol; 2017 Mar; 24(3):645-651. PubMed ID: 28130619
[TBL] [Abstract][Full Text] [Related]
12. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
[TBL] [Abstract][Full Text] [Related]
13. Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial.
Weiss A; Jin Q; Waks AG; Yardley D; Spring LM; Wrabel E; Tayob N; Viale G; Krop IE; King TA; Metzger-Filho O
J Am Coll Surg; 2024 Mar; 238(3):303-311. PubMed ID: 38047578
[TBL] [Abstract][Full Text] [Related]
14. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
15. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
van der Noordaa MEM; van Duijnhoven FH; Cuijpers FNE; van Werkhoven E; Wiersma TG; Elkhuizen PHM; Winter-Warnars G; Dezentje V; Sonke GS; Groen EJ; Stokkel M; Vrancken Peeters MTFD
Br J Surg; 2021 Jun; 108(6):667-674. PubMed ID: 34157085
[TBL] [Abstract][Full Text] [Related]
16. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.
Vila J; Mittendorf EA; Farante G; Bassett RL; Veronesi P; Galimberti V; Peradze N; Stauder MC; Chavez-MacGregor M; Litton JF; Huo L; Kuerer HM; Hunt KK; Caudle AS
Ann Surg Oncol; 2016 Oct; 23(11):3501-3509. PubMed ID: 27216742
[TBL] [Abstract][Full Text] [Related]
17. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
18. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A
Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
[No Abstract] [Full Text] [Related]
20. Nodal positivity in patients with clinically and radiologically node-negative breast cancer treated with neoadjuvant chemotherapy: multicentre collaborative study.
Zaborowski AM; Doogan K; Clifford S; Dowling G; Kazi F; Delaney K; Yadav H; Brady A; Geraghty J; Evoy D; Rothwell J; McCartan D; Heeney A; Barry M; Walsh SM; Stokes M; Kell MR; Allen M; Power C; Hill ADK; Connolly E; Alazawi D; Boyle T; Corrigan M; O'Leary P; Prichard RS
Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38055888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
